Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SCYNEXISLTS:0L49 +8.49%45 EBITDA Margin % is 3,147.66% as of Jun. 2026. GuruFocus rates LTS:0L49 with a GF Score™ of 45/100 and a GF Value™ of $17.91 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 958 Drug Manufacturers companies, SCYNEXIS ranks worse than 88.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SCYNEXIS's EBITDA for the
three
months ended in Jun. 2026 was $7.40 Mil. SCYNEXIS's Revenue for the
three
months ended in Jun. 2026 was $0.24 Mil. Therefore, SCYNEXIS's EBITDA margin for the quarter that ended in Jun. 2026 was 3,147.66%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SCYNEXIS EBITDA Margin % Related Terms
SCYNEXIS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SCYNEXIS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0L49 vs IXHL, ETST, INIS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (LTS:0L49) has a EBITDA Margin % of 3,147.66% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SCYNEXIS and its competitors. According to the industry distribution chart, SCYNEXIS ranks #851 out of 958 companies in the Drug Manufacturers industry, placing it in the top 88.8%.
Is SCYNEXIS's EBITDA Margin % too high?
SCYNEXIS's current EBITDA Margin % is 3,147.66%. The Drug Manufacturers industry median EBITDA Margin % is 12.05. SCYNEXIS's value of 3,147.66% is 26021.7% above this industry median. Based on the distribution chart, SCYNEXIS ranks #851 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SCYNEXIS has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's EBITDA Margin % compare to IXHL and ETST?
According to the Drug Manufacturers industry distribution chart, SCYNEXIS ranks #851 out of 958 companies for EBITDA Margin %. This places SCYNEXIS in the lower half of its industry. The industry median EBITDA Margin % is 12.05. SCYNEXIS's value of 3,147.66% is 26021.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.05, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SCYNEXIS's current EBITDA Margin % of 3,147.66% is 26021.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SCYNEXIS and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SCYNEXIS's current EBITDA Margin % is 3,147.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (LTS:0L49) is currently considered Possible Value Trap. The stock's GF Value™ is $17.91, compared to a current price of $5.27 — trading 70.6% below its estimated fair value. The current EBITDA Margin % is 3,147.66% and 26021.7% above the Drug Manufacturers industry median of 12.05. SCYNEXIS's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SCYNEXIS (LTS:0L49), the current EBITDA Margin % is 3,147.66% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (LTS:0L49) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of $5.27 is trading 70.6% below its estimated GF Value™ of $17.91.
GuruFocus considers SCYNEXIS to be Possible Value Trap.
Key valuation signals for LTS:0L49:
EBITDA Margin %: 3,147.66%
GF Value™: $17.91 vs. price of $5.27 (70.6% below fair value)
Industry Position: 26021.7% above the Drug Manufacturers median (#851 of 958)
No single metric tells the full story. See the LTS:0L49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
45GF Score
Get the complete analysis for LTS:0L49
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L49 has been successfully added to your 
